Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

PubMed

Topics

Medicine

Cancer Oncology

Internal Medicine

Hematology

Molecular Biology

Show all topics

DOI

10.1200/jco.24.00259